Mumbai, Aug. 6 -- Contract development and manufacturing organization (CDMO) Divi's Laboratories Ltd's June-quarter earnings missed estimates due to pricing pressure on its generics business.

While the Hyderabad-based drugmaker's revenue from operations rose 13.7% year-on-year to Rs.2,410 crore, its net profit jumped 26.7% to Rs.545 crore.

On a standalone basis, its net profit stood at Rs.557 crore in the first quarter of 2025-26.

A poll of 18 brokerages by Bloomberg had pegged the revenue at Rs.2,462 crore and net profit at Rs.582.7 crore.

The company's Ebitda increased 17.2% on-year to Rs.729 crore. Its Ebitda margin expanded slightly to 30.25% as against 29.37% a year ago. Ebitda is earnings before interest, taxes, depreciation and...